# Clinical Practice Guidelines Integration

## Cardiology Guidelines

### Acute Coronary Syndrome (ACS) Management

#### STEMI Guidelines (ACC/AHA 2023)

**Primary PCI Strategy:**
- **Door-to-balloon time:** <90 minutes for PCI-capable hospitals
- **Door-to-needle time:** <30 minutes for fibrinolysis
- **Fibrinolytic timing:** Within 12 hours of symptom onset
- **Transfer protocols:** <120 minutes for interfacility transfer

**Medication Protocols:**
1. **Antiplatelet Therapy:**
   - **Aspirin:** 162-325mg chewed immediately
   - **P2Y12 inhibitors:** Loading dose within 10 minutes
   - **Duration:** 12 months dual therapy minimum

2. **Anticoagulation:**
   - **Unfractionated heparin:** 60 U/kg bolus (max 4000 U)
   - **Enoxaparin:** 1 mg/kg SC every 12 hours
   - **Bivalirudin:** Alternative anticoagulation

**Quality Metrics:**
- Percentage receiving PCI within guideline time
- Door-to-balloon time tracking
- Appropriate reperfusion strategy selection

#### NSTEMI/UA Guidelines

**Risk Stratification:**
- **TIMI Risk Score:** Age, vital signs, ECG changes, biomarkers
- **GRACE Score:** In-hospital and 6-month mortality risk
- **Early invasive strategy:** Risk score ≥3 or high-risk features

**Treatment Timing:**
- **High-risk:** Catheterization within 24 hours
- **Intermediate-risk:** Within 72 hours
- **Low-risk:** Conservative management with medical therapy

---

### Heart Failure Guidelines (ACC/AHA 2021)

#### Guideline-Directed Medical Therapy (GDMT)

**Core Medication Classes:**
1. **ACE Inhibitors/ARBs/ARNI:**
   - **Target doses:** Lisinopril 20-40mg, losartan 50-100mg
   - **Sacubitril/valsartan:** Target dose 97/103mg BID

2. **Beta-Blockers:**
   - **Carvedilol:** Target 25mg BID (≤85 kg) or 50mg BID (>85 kg)
   - **Metoprolol succinate:** Target 200mg daily
   - **Bisoprolol:** Target 10mg daily

3. **Aldosterone Antagonists:**
   - **Spironolactone:** 25-50mg daily
   - **Eplerenone:** 50mg daily

4. **SGLT2 Inhibitors:**
   - **Dapagliflozin:** 10mg daily
   - **Empagliflozin:** 10mg daily
   - **Sacubitril/valsartan preferred:** If eligible

**Monitoring Parameters:**
- **Electrolytes:** Potassium and creatinine (1-2 weeks after initiation)
- **Blood pressure:** Target <130/80 mmHg
- **Heart rate:** 50-60 bpm optimal
- **Weight:** Daily monitoring during titration

---

### Atrial Fibrillation Guidelines (AHA/ACC/HRS 2023)

#### Stroke Prevention

**CHA2DS2-VASc Risk Scoring:**
- **Congestive heart failure:** 1 point
- **Hypertension:** 1 point
- **Age ≥75 years:** 2 points
- **Diabetes:** 1 point
- **Stroke/TIA/thromboembolism:** 2 points
- **Vascular disease:** 1 point
- **Age 65-74 years:** 1 point
- **Sex category (female):** 1 point

**Anticoagulation Recommendations:**
- **Men:** CHA2DS2-VASc ≥2 (consider if ≥1)
- **Women:** CHA2DS2-VASc ≥3 (consider if ≥2)
- **Annual bleeding risk assessment:** HAS-BLED score

#### Rate vs. Rhythm Control

**Rate Control (First-line for most patients):**
- **Target heart rate:** <110 bpm at rest
- **Medications:** Beta-blockers, diltiazem, digoxin
- **AV node ablation:** For permanent AF with symptoms

**Rhythm Control:**
- **Cardioversion:** Recent onset (<48 hours) or post-anticoagulation
- **Maintenance therapy:** Flecainide, sotalol, dronedarone
- **Ablation:** Antiarrhythmic drug failure or patient preference

---

## Oncology Guidelines

### Breast Cancer Management (NCCN 2024)

#### Staging and Risk Assessment

**Tumor Characteristics:**
- **Size:** T1 ≤2cm, T2 2-5cm, T3 >5cm
- **Node status:** N0 (negative), N1 (1-3 nodes), N2 (4-9 nodes)
- **Hormone receptors:** ER/PR status for endocrine therapy
- **HER2 status:** Overexpression for targeted therapy

**Multigene Assays:**
- **Oncotype DX:** Score 0-100 for recurrence risk
- **MammaPrint:** Low vs. high risk classification
- **PAM50:** Intrinsic subtype determination

#### Systemic Therapy

**Hormone Receptor-Positive Disease:**
- **Premenopausal:** Tamoxifen + ovarian suppression
- **Postmenopausal:** Aromatase inhibitor ± ovarian suppression
- **Duration:** 5-10 years total therapy

**HER2-Positive Disease:**
- **Trastuzumab:** 1 year standard duration
- **Pertuzumab:** Addition for node-positive disease
- **T-DM1:** Alternative for residual disease after neoadjuvant therapy

**Triple-Negative Disease:**
- **Chemotherapy:** Anthracycline + taxane based
- **Pembrolizumab:** PD-L1 positive (CPS ≥10)
- **PARP inhibitors:** BRCA1/2 mutations

---

### Colon Cancer Management (NCCN 2024)

#### Staging and Resectability

**TNM Staging System:**
- **T1:** Invasion of submucosa
- **T2:** Invasion of muscularis propria
- **T3:** Invasion through muscularis propria
- **T4:** Invasion of adjacent structures

**Resectability Assessment:**
- **Resectable:** No distant metastases, surgical margins achievable
- **Borderline resectable:** Possible with neoadjuvant therapy
- **Unresectable:** Distant metastases or locally advanced

#### Adjuvant Therapy

**Stage III Disease:**
- **Oxaliplatin-based regimen:** FOLFOX or CAPEOX
- **Duration:** 6 months standard
- **CAPEOX alternative:** 3 months if suitable

**Stage II Disease:**
- **High-risk features:** T4, <12 lymph nodes, perforation, poor differentiation
- **Benefit-risk discussion:** 12-16% benefit in high-risk patients

#### Metastatic Disease

**First-Line Therapy:**
- **FOLFIRI or FOLFOX:** Combination therapy
- **Bevacizumab:** All comers benefit
- **Cetuximab/panitumumab:** KRAS wild-type tumors only

---

### Lung Cancer Management (NCCN 2024)

#### Non-Small Cell Lung Cancer (NSCLC)

**Molecular Testing (Essential):**
- **EGFR mutations:** Sensitivity to EGFR inhibitors
- **ALK rearrangements:** Sensitivity to ALK inhibitors
- **ROS1 rearrangements:** ROS1 inhibitor sensitivity
- **PD-L1 expression:** Immunotherapy selection

**Targeted Therapy:**
- **EGFR-mutated:** Osimertinib (first-line)
- **ALK-rearranged:** Alectinib (first-line)
- **ROS1-rearranged:** Entrectinib (first-line)

#### Small Cell Lung Cancer (SCLC)

**Limited Disease:**
- **Chemoradiation:** Cisplatin/etoposide with radiation
- **Prophylactic cranial irradiation:** Consider for responders
- **Durvalumab consolidation:** Following chemoradiation

**Extensive Disease:**
- **Chemotherapy:** Platinum/etoposide
- **Immunotherapy:** Atezolizumab or durvalumab
- **Prophylactic cranial irradiation:** Selected patients

---

## Neurology Guidelines

### Stroke Management (ASA 2023)

#### Acute Ischemic Stroke

**IV Thrombolysis:**
- **Time window:** <4.5 hours from symptom onset
- **Dose:** Alteplase 0.9 mg/kg (maximum 90mg)
- **Contraindications:** See comprehensive list
- **Monitoring:** NIHSS every 15 minutes × 2 hours

**Mechanical Thrombectomy:**
- **Large vessel occlusion:** Internal carotid, M1/M2 MCA, basilar
- **Time window:** <24 hours with perfusion imaging
- **Target:** TICI 2b-3 reperfusion
- **Institutions:** Comprehensive stroke centers

#### Secondary Prevention

**Antiplatelet Therapy:**
- **Aspirin:** 81-325mg daily (starting 24 hours post-tPA)
- **Clopidogrel:** Alternative if aspirin intolerant
- **Dual therapy:** 21-90 days post-minor stroke/TIA

**Risk Factor Management:**
- **Blood pressure:** Target <130/80 mmHg
- **Statin therapy:** High-intensity for all stroke patients
- **Anticoagulation:** Atrial fibrillation management

---

### Epilepsy Management (ILAE 2023)

#### Status Epilepticus Protocol

**First-Line Treatment:**
- **Lorazepam:** 0.1 mg/kg IV (maximum 4mg)
- **Alternative:** Midazolam 0.2 mg/kg IM (if no IV access)

**Second-Line Treatment:**
- **Fosphenytoin:** 20 mg PE/kg IV
- **Alternative:** Valproic acid 40 mg/kg IV

**Refractory Status:**
- **Propofol:** 2 mg/kg bolus, then infusion
- **Midazolam:** 0.2 mg/kg bolus, then infusion
- **Consider:** Pentobarbital coma

#### Antiepileptic Drug Selection

**First-Generation AEDs:**
- **Phenytoin:** Renal clearance, protein binding
- **Carbamazepine:** Hepatic metabolism, autoinduction
- **Phenobarbital:** Long half-life, sedation

**Second-Generation AEDs:**
- **Lamotrigine:** Rash risk, titrate slowly
- **Levetiracetam:** Minimal drug interactions
- **Topiramate:** Weight loss, cognitive effects

---

### Parkinson's Disease (MDS 2023)

#### Motor Symptom Management

**Initial Therapy:**
- **Levodopa:** Most effective for motor symptoms
- **Dopamine agonists:** Younger patients, motor complications
- **MAO-B inhibitors:** Early disease, neuroprotective potential

**Motor Fluctuations:**
- **Wearing-off:** Increase levodopa frequency
- **Delayed-on:** Carbidopa/levodopa dispersible
- **Dose failure:** Higher doses or adjuvants

**Dyskinesia Management:**
- **Amantadine:** For dyskinesia reduction
- **Deep brain stimulation:** For severe motor complications

#### Non-Motor Symptoms

**Cognitive Impairment:**
- **Cholinesterase inhibitors:** Rivastigmine
- **Memantine:** Moderate to severe disease

**Orthostatic Hypotension:**
- **Fludrocortisone:** Salt retention
- **Midodrine:** Vasoconstriction
- **Non-pharmacological:** Compression stockings, increased salt

---

## Emergency Medicine Guidelines

### Sepsis Management (SSC 2021)

#### Surviving Sepsis Campaign Hour-1 Bundle

**Immediate Actions:**
1. **Measure lactate level** (repeat if >2 mmol/L)
2. **Obtain blood cultures** before antibiotics
3. **Administer broad-spectrum antibiotics**
4. **Begin rapid fluid resuscitation** (30 mL/kg crystalloid)
5. **Apply vasopressors** if hypotensive during/after fluid resuscitation
   - Target MAP ≥65 mmHg

#### Antibiotic Selection

**Community-Acquired Pneumonia:**
- **Ceftriaxone + azithromycin** (moderate-severe)
- **Levofloxacin** (monotherapy)

**Healthcare-Associated:**
- **Piperacillin-tazobactam** + vancomycin
- **Ceftazidime** + vancomycin

**Urinary Tract:**
- **Ceftriaxone** or **ciprofloxacin**

#### Fluid Management
- **Crystalloids:** 30 mL/kg within 3 hours
- **Albumin:** Consider in septic shock
- **Vasopressors:** Norepinephrine first-line

---

### Trauma Management (ACS ATLS 10th Edition)

#### Primary Survey (ABCDE)

**Airway:**
- **Cervical spine protection**
- **Assess airway patency**
- **Emergency airway** if compromised

**Breathing:**
- **Auscultate chest**
- **Identify tension pneumothorax**
- **Provide oxygen**

**Circulation:**
- **Control hemorrhage**
- **Establish IV access**
- **Fluid resuscitation**

**Disability:**
- **Glasgow Coma Scale**
- **Pupil response**
- **Lateralizing signs**

**Exposure:**
- **Full exposure**
- **Prevent hypothermia**

#### Secondary Survey

**Head-to-toe examination:**
- **Comprehensive history**
- **Systematic physical exam**
- **Priority imaging studies**
- **Specialist consultations**

---

## Quality Measures and Outcomes

### Cardiovascular Quality Metrics

**Acute MI Metrics:**
- Door-to-needle time for thrombolysis
- Door-to-balloon time for PCI
- Aspirin within 24 hours
- Beta-blocker at discharge
- Statin therapy at discharge

**Heart Failure Metrics:**
- Discharge instructions
- Left ventricular function assessment
- ACE inhibitor/ARB for LVSD
- Beta-blocker for LVSD
- 30-day readmission rate

### Oncology Quality Metrics

**Breast Cancer:**
- HER2 testing completion rate
- Sentinel lymph node biopsy rate
- Adjuvant therapy completion rates
- Time to treatment initiation

**Colon Cancer:**
- Adequate lymph node harvest (≥12 nodes)
- Appropriate adjuvant therapy for stage III
- 30-day surgical mortality
- Quality of life measures

### Neurology Quality Metrics

**Stroke:**
- Door-to-needle time
- IV thrombolysis within 3 hours
- Antithrombotic therapy at discharge
- Stroke education provided
- 30-day mortality

### Emergency Medicine Metrics

**Sepsis:**
- Time to antibiotics
- Fluid resuscitation within 3 hours
- Lactate measurement
- Blood culture before antibiotics
- Bundle compliance rate

**Trauma:**
- Time to CT scan
- Time to surgery
- Injury severity score documentation
- Specialist consultation timely

---

## Evidence Integration and Implementation

### Clinical Decision Support

**Order Sets:**
- Standardized medication protocols
- Diagnostic imaging pathways
- Laboratory monitoring schedules
- Follow-up appointment templates

**Best Practice Alerts:**
- Appropriate antimicrobial selection
- Drug interaction warnings
- Dosing adjustments for kidney function
- Allergy cross-reactivity

### Performance Improvement

**Data Collection:**
- Electronic health record integration
- Automated metric calculation
- Real-time feedback systems
- Benchmarking against national standards

**Continuous Quality Improvement:**
- Root cause analysis for outliers
- Multidisciplinary improvement teams
- Regular guideline updates
- Provider education programs

---

*Note: These guidelines represent evidence-based recommendations and should be adapted to individual patient circumstances and local practice patterns.*